| Extra | An initial rapid response (5 to 30 minutes) is characterized by vasodilation, increased vascular permeability, bronchial smooth muscle contraction, and glandular secretions. This is driven by preformed mediators stored in secretory vacuoles and typically resolves within 60 minutes: Biogenic amines (e.g., histamine): Bronchial smooth muscle contraction, increased vascular permeability and dilation, and increased mucous secretion Enzymes contained in granule matrix (e.g., chymase, tryptase): Generate kinins and activated complement by cleaving precursor proteins Proteoglycans (e.g., heparin) A second (delayed) phase, with onset 2 to 24 hours after initial allergen exposure is characterized by inflammatory cell infiltrates and tissue damage (especially epithelium). It can persist for days and is driven by lipid mediators and cytokines produced by the activated mast cells: Lipid mediators are produced from precursors released from mast cell membranes by phospholipase A2 Leukotriene B4: Highly chemotactic for neutrophils, monocytes, and eosinophils Leukotrienes C4, D4, and E4: Thousand-fold more potent than histamine for increasing vascular permeability and bronchial smooth muscle contraction Prostaglandin D2: Intense bronchospasm and mucous secretion Platelet-activating factor (PAF): Platelet aggregation, histamine release, bronchoconstriction, vasodilation, and increased vascular permeability; chemotactic for neutrophils and eosinophils and can cause activation with degranulation Cytokine mediators recruit and activate inflammatory cells; these include tumor necrosis factor (TNF), IL-1, and chemokines. IL- 4 released from mast cells amplifies the TH2 response. The consequences of mast cell activation are schematized in Figure 6.15
 |